Zacks Investment Research cut shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) from a buy rating to a hold rating in a research note issued to investors on Wednesday.
According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “
Xenetic Biosciences (XBIO) opened at $2.64 on Wednesday. Xenetic Biosciences has a 52 week low of $1.75 and a 52 week high of $5.90.
Xenetic Biosciences (NASDAQ:XBIO) last posted its earnings results on Monday, August 14th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.13). equities analysts expect that Xenetic Biosciences will post -0.89 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2017/11/05/xenetic-biosciences-inc-xbio-downgraded-by-zacks-investment-research.html.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Xenetic Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Xenetic Biosciences Inc. and related companies.